Workflow
Lante Optics(688127)
icon
Search documents
蓝特光学:预计今年微棱镜市场需求仍将保持增长
Ju Chao Zi Xun· 2025-07-23 03:59
2025年上半年度,手机端潜望式长焦微棱镜的市场需求进一步扩张、高阶玻塑混合镜头项目逐步落地,汽车端随着行业内智驾下沉的趋势也 有望继续形成市场增量;此外,消费电子、光通讯、半导体等领域的市场需求也呈现良好的增长趋势,公司也在积极拓展相关业务合作的广 度与深度。 随着AI技术的日趋成熟,消费级的AR头显、AI眼镜正在逐步量产落地——其中,AR头显中的光波导显示组件作为核心组件,具有较高的价值 量,是未来若干年内值得重视的潜在市场。 模造玻璃方面,除了前期已开发的汽车电子应用和正在积极投入的手机玻塑混合镜头应用,近年来公司面对的高速光模块、手持影像创作设 备等领域需求也迎来了较快的增长,对公司玻璃非球面透镜业务的稳定发展起到了支撑作用。 近日,蓝特光学在接受机构调研时表示,微棱镜业务是公司近两年培育的一大核心业务,其中"新型微棱镜"产品有别于市场主流的微棱镜产 品,在产品与工艺设计上更为复杂,价值量相对较高,公司今年继续跟进客户新机型的升级需求,叠加2024年已推出机型持续销售,预计 2025年市场总需求仍将保持增长;同时,公司同步开发了其他类微棱镜产品,进一步完善了公司在该业务领域的产品矩阵,目前也已启动出 ...
上证智能家居指数报3366.23点,前十大权重包含工业富联等
Jin Rong Jie· 2025-07-21 08:43
从上证智能家居指数持仓的市场板块来看,上海证券交易所占比100.00%。 从上证智能家居指数持仓样本的行业来看,信息技术占比60.15%、可选消费占比21.89%、通信服务占 比12.21%、工业占比5.74%。 资料显示,指数样本每半年调整一次,样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整,调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前,权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时,将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理,参照计算与维护细则处理。 金融界7月21日消息,上证指数高开高走,上证智能家居指数 (沪智家居,H50056)报3366.23点。 数据统计显示,上证智能家居指数近一个月上涨5.01%,近三个月上涨3.70%,年至今上涨8.44%。 据了解,上证智能家居指数从沪市证券中选取智能家居零部件应用厂商、终端设备厂商、系统集成商、 网络和内容服务商等与智能家居相关的上市公司证券作为指数样本,以反映沪市智能家居上市公司证券 的整体表现该指数以2012年06月29日为基日,以1000.0 ...
电子行业深度:智能眼镜:AI形态领航,探索AR新视界
Minsheng Securities· 2025-06-12 00:23
Investment Rating - The report maintains a "Recommended" rating for key companies in the smart glasses industry, including GoerTek, Lante Optics, Sunny Optical Technology, Espressif Technology, and others [5][6]. Core Insights - Smart glasses are identified as one of the most promising carriers for AI large models, with the potential for significant transformation in human-computer interaction due to advancements in AI capabilities [1][11]. - The market consensus on AI glasses has evolved, particularly with the launch of RayBan Meta, which combines hardware, AI functionality, and user-friendly features, achieving sales of over 1.4 million units in 2024 [2][20]. - The integration of optical display modules is crucial for the evolution of smart glasses towards augmented reality (AR) applications, with a focus on lightweight and high-performance optical components [3][23]. Summary by Sections Smart Glasses: AI First, Exploring AR - The report discusses the transition of AI from research to application, highlighting the increasing importance of multi-modal interactions, including text, images, and voice [11][13]. - Smart glasses are positioned as a suitable platform for AI applications due to their proximity to key sensory organs, enabling seamless interaction with AI [16][19]. Optical Waveguide and Micro LED as Core Bottlenecks - The report identifies the challenges in optical module manufacturing, emphasizing the need for lightweight and high-performance solutions to facilitate mass production of AR glasses [3][34]. - The combination of diffraction waveguides and Micro LED technology is seen as a potential solution for enhancing the display and user experience of AR glasses [3][39]. Investment Recommendations - The report suggests focusing on various segments within the smart glasses industry, including brands, solution providers, and optical component manufacturers, highlighting companies like Xiaomi, GoerTek, and Lante Optics as key players [4][5]. - The report emphasizes the importance of SoC processors for AI glasses and optical components for AR glasses, indicating a clear distinction in hardware requirements between the two types [26][28].
蓝特光学实控人方拟减持 2020年上市即巅峰募6.3亿
Zhong Guo Jing Ji Wang· 2025-06-05 03:31
Core Viewpoint - The announcement reveals a share reduction plan by major shareholders of Lante Optics, indicating potential changes in shareholding structure without affecting the company's governance or control [1][2]. Group 1: Share Reduction Details - Shareholder Jiaxing Lantuo plans to reduce up to 2,130,000 shares, representing 0.5283% of the total share capital, within three months after a 15-day notice period [1]. - Shareholder Xu Guiming intends to reduce up to 1,292,200 shares, accounting for 0.3205% of the total share capital, under the same timeline [1]. - As of the announcement date, Jiaxing Lantuo holds 8,520,000 shares (2.1131% of total) and Xu Guiming holds 5,168,800 shares (1.2820% of total) [1]. Group 2: Company Background and Financials - Lante Optics was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 21, 2020, with an initial issuance of 40.9 million shares at a price of 15.41 yuan per share [2]. - The company raised a total of 630 million yuan, with a net amount of 555 million yuan after deducting issuance costs, which was 152 million yuan less than the original plan of 707 million yuan [2]. - The funds raised are intended for high-precision glass wafer production base construction, micro-prism production base construction, and working capital supplementation [2].
蓝特光学: 股东减持股份计划公告
Zheng Quan Zhi Xing· 2025-06-04 12:24
(以下简称"嘉兴蓝拓")持有公司股份 股,占公司总股本的 1.2820%。上述股份来源均为公司首次公开发行前股份,且 均已解除限售并上市流通。 证券代码:688127 证券简称:蓝特光学 公告编号:2025-020 浙江蓝特光学股份有限公司 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示: ? 股东持股的基本情况 截至本公告披露日,浙江蓝特光学股份有限公司(以下简称"公司")股东 嘉兴蓝拓股权投资合伙企业(有限合伙) ? 减持计划的主要内容 股东徐桂明先生拟自本公告发布之日起的 15 个交易日后至未来 3 个月内, 通过集中竞价及大宗交易方式减持其直接持有的公司首次公开发行前的股份,减 持数量不超过 1,292,200 股,占公司总股本比例 0.3205%。徐桂明先生持有的公 司首次公开发行前的股份已于 2023 年 9 月 21 日解除限售并上市流通。 | 一、减持主体的基本情况 | | | | | | | | | | --- | --- | --- | --- | --- | --- | -- ...
蓝特光学(688127) - 股东减持股份计划公告
2025-06-04 11:18
浙江蓝特光学股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律 责任。 证券代码:688127 证券简称:蓝特光学 公告编号:2025-020 重要内容提示: 股东持股的基本情况 截至本公告披露日,浙江蓝特光学股份有限公司(以下简称"公司")股东 嘉兴蓝拓股权投资合伙企业(有限合伙)(以下简称"嘉兴蓝拓")持有公司股份 8,520,000 股,占公司总股本的 2.1131%;股东徐桂明先生持有公司股份 5,168,800 股,占公司总股本的 1.2820%。上述股份来源均为公司首次公开发行前股份,且 均已解除限售并上市流通。 减持计划的主要内容 嘉兴蓝拓股权投资合伙企业(有限合伙)拟自本公告发布之日起的 15 个交 易日后至未来 3 个月内,通过集中竞价及大宗交易方式减持其直接持有的公司首 次公开发行前的股份,减持数量不超过 2,130,000 股,占公司总股本比例 0.5283%。 嘉兴蓝拓股权投资合伙企业(有限合伙)持有的公司首次公开发行前的股份已于 2023 年 9 月 21 日解 ...
蓝特光学:股东嘉兴蓝拓和徐桂明拟分别减持0.5283%和0.3205%公司股份
news flash· 2025-06-04 11:02
Summary of Key Points - The company Lante Optics announced that shareholder Jiaxing Lantuo Equity Investment Partnership (Limited Partnership) plans to reduce its holdings by no more than 2.13 million shares, which accounts for 0.5283% of the company's total share capital [1] - Shareholder Mr. Xu Guiming intends to reduce his holdings by no more than 1.2922 million shares, representing 0.3205% of the company's total share capital [1]
蓝特光学(688127) - 2024年年度权益分派实施公告
2025-06-03 11:15
证券代码:688127 证券简称:蓝特光学 公告编号:2025-019 浙江蓝特光学股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 每股现金红利0.20元 相关日期 | 股权登记日 | 除权(息)日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/9 | 2025/6/10 | 2025/6/10 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 15 日的2024年年度股东大会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后,在中国证券登记结算有限责任 公司上海分公司(以下简称"中国结算上海分公司")登记在册的本公司全体股东。 3. 分配方案: 1. 发放年度:2024年年度 2. 分派对象: 三、 相关日期 | 股权登记日 | 除权(息)日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/9 | 2025/6/10 | 2025/6/10 ...
5月26日晚间重要公告一览
Xi Niu Cai Jing· 2025-05-26 10:11
Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]
蓝特光学: 董事减持股份结果公告
Zheng Quan Zhi Xing· 2025-05-25 08:22
Summary of Key Points Core Viewpoint - The announcement details the shareholding and reduction plan of Wang Fangli, a director of Zhejiang Lante Optical Co., Ltd, highlighting the completion of a share reduction plan and the current shareholding status of the director [1][2]. Group 1: Shareholding Information - Wang Fangli held 54,414,400 shares before the reduction, representing 13.4959% of the total share capital of the company [1][2]. - The shares were acquired prior to the company's initial public offering (IPO) and were released from restrictions on September 21, 2023 [1]. Group 2: Reduction Plan Implementation - The reduction plan was disclosed on January 23, 2025, with a maximum intended reduction of 6,047,886 shares, which would account for 1.5000% of the total share capital [1][2]. - As of the end of the reduction period, Wang Fangli successfully reduced his holdings by 4,853,379 shares, which is 1.2037% of the total share capital [1][2]. - The reduction was executed through a combination of centralized bidding (2,453,379 shares) and block trading (2,400,000 shares) [2]. - The reduction price ranged from 21.00 to 28.40 yuan per share, totaling approximately 117.71 million yuan [2]. - The reduction plan did not reach the maximum limit, with 1,194,507 shares remaining untransacted [2]. Group 3: Current Shareholding Status - Following the reduction, Wang Fangli currently holds 49,561,021 shares, which is 12.2922% of the total share capital [2]. - The actual reduction was consistent with the previously disclosed plan, and the plan was not terminated early [2].